Community acquired pneumonia (CAP) 30 days mortality and biomarkers Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity Year: 2010
Platelet activation is boosted early in community-acquired pneumonia and sustained until 30 days later Source: International Congress 2018 – Pneumonia: from the community to the intensive care unit Year: 2018
A delay in reaching time to clinical stability (tcs) for hospitalized patients with community-acquired pneumonia (CAP) is associated with failure within 30 days after hospital discharge Source: Annual Congress 2009 - Ventilator-associated pneumonia, severe community-acquired pneumonia and healthcare associated pneumonia Year: 2009
Correlation between pneumonia severity index and mortality within 30 days after the diagnosis of community-acquired pneumonia in elderly subjects Source: Eur Respir J 2006; 28: Suppl. 50, 741s Year: 2006
Profile of selected cytokines in serum and in BAL-fluid in patients with cryptogenic organising pneumonia before and after 3 months of calrithromycin treatment Source: Annual Congress 2010 - Usefulness of bronchoalveolar lavage in diffuse parenchymal lung disease Year: 2010
To establish the characteristics which influence patients with an acute exacerbation of COPD to die within 2 weeks of hospital admission compared to those after a 2-week period Source: Eur Respir J 2005; 26: Suppl. 49, 283s Year: 2005
Pre-24 hours hospital lethality of patients with community-acquired pneumonia Source: Eur Respir J 2004; 24: Suppl. 48, 548s Year: 2004
Predicting factors of pulmonary functional sequelae in COVID-19 patients after 4 months from hospital admission Source: Virtual Congress 2021 – Long COVID - 19 Year: 2021
Organizing pneumonia – characteristics of 37 patients Source: Eur Respir J 2006; 28: Suppl. 50, 307s Year: 2006
Effect on outcome of antibiotic treatment during the 2 weeks before hospital admission for community acquired pneumonia Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations Year: 2010
A longitudinal modelling study estimates acute symptoms of community acquired pneumonia recover to baseline by 10 days Source: Eur Respir J, 49 (6) 1602170; 10.1183/13993003.02170-2016 Year: 2017
Severe COVID-19 pneumonia: clinical, functional, and imaging outcomes at 4 months Source: Virtual Congress 2021 – Chronic COVID - 19 Year: 2021
Clinical judgement on top of CURB65-score in predicting 30 days clinical outcome in patients with community acquired pneumonia (CAP) admitted to the hospital Source: International Congress 2014 – Pathogenesis and mechanisms of respiratory infections Year: 2014
Prognostic factors of 30 day mortality in HIV infected patients with community-acquired pneumonia Source: International Congress 2014 – Interventions and other therapeutic approaches in respiratory infections Year: 2014
The effectiveness of carrying out 6 month and 1 year re-assessments for respiratory patients post pulmonary rehabilitation Source: Annual Congress 2012 - Physiotherapy and rehabilitation strategies in respiratory diseases and beyond Year: 2012
Sedation in COPD patients mechanically ventilated due to acute respiratory failure: the prognostic effects of its duration more than 24 hours Source: Eur Respir J 2006; 28: Suppl. 50, 395s Year: 2006
Predictors of hypoxic respiratory failure in COPD patients during 30 months of follow-up Source: Annual Congress 2010 - Thoracic dynamics and dyspnoea on exercise Year: 2010
Respiratory failure 4 months after severe SARS-Cov-2 infection Source: Virtual Congress 2021 – CCC Respiratory infections Year: 2021
Outcomes of 6-9-12 months’ bedaquiline-containing regimens in MDR/XDR TB after 24 months follow up Source: International Congress 2018 – Drug-resistant tuberculosis Year: 2018
Definition of severity and the reasons for hospitalization (RH) in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2005; 26: Suppl. 49, 641s Year: 2005